Abstract:Abstract Receptor activator of NF‐κB ligand (RANKL) stimulation leads to the activation of mitogen‐activated protein kinase (MAPK)/AP‐1 and Ca 2+ –nuclear factor of activated T‐cells cytoplasmic 1 (NFATc1) signaling pathways in osteoclastogenesis. Targeting these pathways has been an encouraging strategy for bone‐related diseases, such as postmenopausal osteoporosis. In this study, we examined the effects of caffeic acid 3,4‐dihydroxy‐phenethyl ester (CADPE) on osteoclastogenesis. In mouse bone marrow monocytes (BMMs) and RAW264.7 cells, CADPE suppressed RANKL‐induced osteoclast differentiation and actin‐ring formation in a dose‐dependent manner within non–growth inhibitory concentrations at the early stage, while CADPE had no effect on macrophage colony‐stimulating factor (M‐CSF)‐induced proliferation and differentiation. At the molecular level, CADPE inhibited RANKL‐induced phosphorylation of MAPKs, including extracellular signal‐regulated kinases 1/2 (ERK1/2), p38, and c‐Jun N‐terminal kinase (JNK), without significantly affecting the NF‐κB signaling pathway. CADPE abrogated RANKL‐induced activator protein 1 (AP‐1)/FBJ murine osteosarcoma viral oncogene homolog (c‐Fos) nuclear translocation and activation. Overexpression of c‐Fos prevented the inhibition by CADPE of osteoclast differentiation. Furthermore, CADPE suppressed RANKL‐induced the tumor necrosis factor receptor associated factor 6 (TRAF6) interaction with c‐src tyrosine kinase (c‐Src), blocked RANKL‐induced the phosphorylation of protein kinase B (AKT), and inhibited RANKL‐induced Ca 2+ oscillation. As a result, CADPE decreased osteoclastogenesis‐related marker gene expression, including NFATc1 , TRAP , cathepsin K , and c‐Src . To test the effects of CADPE on osteoclast activity in vivo, we showed that CADPE prevented ovariectomy‐induced bone loss by inhibiting osteoclast activity. Together, our data demonstrate that CADPE suppresses osteoclastogenesis and bone loss through inhibiting RANKL‐induced MAPKs and Ca 2+ ‐NFATc1 signaling pathways. CADPE is a novel agent in the treatment of osteoclast‐related diseases, such as osteoporosis. © 2012 American Society for Bone and Mineral Research.

Mycoepoxydiene suppresses RANKL-induced osteoclast differentiation and reduces ovariectomy-induced bone loss in mice

Isoalantolactone Inhibits RANKL-induced Osteoclast Formation Via Multiple Signaling Pathways

Cirsilineol inhibits RANKL-induced osteoclast activity and ovariectomy-induced bone loss via NF-κb/ERK/p38 signaling pathways

Administration of SB239063 Ameliorates Ovariectomy-Induced Bone Loss Via Suppressing Osteoclastogenesis in Mice

Evodiamine inhibits RANKL-induced osteoclastogenesis and prevents ovariectomy-induced bone loss in mice.

Cirsilineol inhibits RANKL-induced osteoclast activity and ovariectomy-induced bone loss via NK-κβ/ERK/p38 signaling pathways

Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand-induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+-nuclear fact

Inhibitory effects of Mycoepoxydiene on macrophage foam cell formation and atherosclerosis in ApoE-deficient mice

Mycoepoxydiene Inhibits Lipopolysaccharide-Induced Inflammatory Responses Through the of TRAF6 Polyubiquitination

Madecassoside Inhibits Estrogen Deficiency‐induced Osteoporosis by Suppressing RANKL‐induced Osteoclastogenesis

12-Deoxyphorbol 13-Acetate Inhibits RANKL-induced Osteoclastogenesis Via the Attenuation of MAPK Signaling and NFATc1 Activation

Mycoepoxydiene Inhibits Activation of BV2 Microglia Stimulated by Lipopolysaccharide Through Suppressing NF-κB, ERK 1/2 and Toll-Like Receptor Pathways.

3-(4-Methoxyl)-1-(2-(4-coumarin)prop)-2-en-1-one Inhibits the Differentiation of Osteoclasts

Tectorigenin inhibits RANKL-induced osteoclastogenesis via suppression of NF-κB signalling and decreases bone loss in ovariectomized C57BL/6.

A Novel Diterpenoid Suppresses Osteoclastogenesis and Promotes Osteogenesis by Inhibiting Ifrd1-Mediated and IκBα-Mediated p65 Nuclear Translocation.

Inhibiting Monoacylglycerol Lipase Suppresses RANKL-Induced Osteoclastogenesis and Alleviates Ovariectomy-Induced Bone Loss

Methyl 3,4-dihydroxybenzoate inhibits RANKL-induced osteoclastogenesis via Nrf2 signaling in vitro and suppresses LPS-induced osteolysis and ovariectomy-induced osteoporosis in vivo

Pectolinarigenin Prevents Bone Loss in Ovariectomized Mice and Inhibits RANKL‐induced Osteoclastogenesis Via Blocking Activation of MAPK and NFATc1 Signaling

Mycoepoxydiene, a fungal polyketide inhibits MCF-7 cells through simultaneously targeting p53 and NF-κB pathways.

Structure-based Development of an Osteoprotegerin-Like Glycopeptide That Blocks RANKL/RANK Interactions and Reduces Ovariectomy-Induced Bone Loss in Mice.